Loading company…
NanoRibo develops RNA therapeutics designed to modulate immune responses to cancer.
Founded in 2021, NanoRibo develops RNA-based therapies intended to modulate immune responses against cancer. The company is based in Shanghai, China, and works with healthcare providers and research institutions. In January 2026, Chengdu Kanghua Biological Products Co.,Ltd., a portfolio company of Yingke Private Equity, agreed to fully acquire NanoRibo.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in